4/A: Outlook Therapeutics Insider Amends Filing to Reflect Warrant Exercise and Share Receipt

Ghiath M. Sukhtian, a director and 10% owner of Outlook Therapeutics, amends a previous filing to accurately report the receipt of shares from warrant exercises and correct the transaction date.

Summary

• Ghiath M. Sukhtian, a director and 10% owner of Outlook Therapeutics, filed an amendment to a Form 4 on March 12, 2025, to correct a previous filing regarding warrant exercises.
• The amendment clarifies the receipt of 3,458,571 shares of common stock on January 17, 2025, at a price of $2.51 per share, resulting from the exercise of warrants.
• The filing also involves GMS Ventures & Investments, where Sukhtian holds a controlling interest and which has representatives on Outlook Therapeutics' board.
• Following the reported transaction, Sukhtian indirectly beneficially owns 9,266,645 shares through GMS Ventures.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to warrant exercises, which can be seen as a moderately positive sign of insider confidence, but it's primarily a procedural matter.

Industry Context

Insider transactions are routinely monitored as indicators of management's confidence in the company's prospects. Warrant exercises can be seen as a positive sign, indicating the warrant holder believes the stock's value will increase.

Related Party Transactions

• The warrant exercise inducement offer letter agreement between Outlook Therapeutics and GMS Ventures, where Ghiath Sukhtian has a controlling interest, constitutes a related party transaction.

Stakeholder Impact

• The warrant exercise increases the number of outstanding shares, which could potentially dilute existing shareholders' ownership.

Key Dates